Last update Sept. 4, 2021

Ticlopidine Hydrochloride

High Risk

Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.

Platelet antiaggregant indicated in the prevention and treatment of thromboembolic disorders.
Oral administration in two daily doses.

At the date of the last update we did not find any published data on its excretion in breast milk.

Its very high percentage of plasma protein binding makes it difficult excretion in breast milk in significant quantities, but its long elimination half-life would facilitate it.

Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable (Hale, Serrano 2015, Briggs 2015, Schaefer 2015), especially during the neonatal period and in the event of prematurity.

Alternatives

  • Aspirin (Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)
  • Clopidogrel (Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)
  • Dipyridamole (Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Ticlopidine Hydrochloride in other languages or writings:

Group

Ticlopidine Hydrochloride belongs to this group or family:

Tradenames

Main tradenames from several countries containing Ticlopidine Hydrochloride in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 90 %
Molecular weight 264 daltons
Protein Binding 98 %
Tmax 3 hours
30 - 50 (1 dos: 8-20) hours

References

  1. Hale TW. Medications & Mothers' Milk. 1991- . Springer Publishing Company. Available from https://www.halesmeds.com Consulted on April 10, 2024 Full text (link to original source)
  2. AEMPS. Ticlopidina. Ficha técnica. 2021 Full text (in our servers)
  3. Serrano Aguayo P, García de Quirós Muñoz JM, Bretón Lesmes I, Cózar León MV. Tratamiento de enfermedades endocrinológicas durante la lactancia. [Endocrinologic diseases management during breastfeeding.] Med Clin (Barc). 2015 Jan 20;144(2):73-9. Abstract
  4. Briggs GG, Freeman RK, Towers CV, Forinash AB. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Wolters Kluwer Health. Tenth edition (acces on line) 2015
  5. Schaefer C, Peters P, Miller RK. Drugs During Pregnancy and Lactation. Treatment options and risk assessment. Elsevier, Third Edition. 2015
  6. Mylan Ph. Ticlopidine Drug summary. 2011 Full text (in our servers)

Total visits

4,233

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Confederación Nacional de Pediatría (CONAPEME) of Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM